Prediabetes is associated with HNF-4 α P2 promoter polymorphism rs1884613: a case-control study in Han Chinese population and an updated meta-analysis.
BACKGROUND
Controversy remains for the association between hepatocyte nuclear factor 4α (HNF-4α) P2 promoter polymorphism rs1884613 and type 2 diabetes (T2D). There was no association test of this polymorphism with prediabetes and T2D in the Chinese population. Moreover, an updated meta-analysis in various ethnic groups is needed to establish the contribution of rs1884613 to T2D risk.


METHODS
Using the Sequenom MassARRAY platform approach, we genotyped rs1884613 of HNF-4α in the P2 promoter region among 490 T2D patients, 471 individuals with prediabetes, and 575 healthy controls. All the individuals were recruited from 16 community health service centers in Nanshan district in Shenzhen province. Using STATA 11.0 software, meta-analysis was performed to summarize the overall contribution of rs1884613 to T2D risk.


RESULTS
Polymorphism rs1884613 was associated with genetic susceptibility to prediabetes in the whole samples (OR = 1.40, 95% CI = 1.16-1.68, P = 0.0001) and the female subgrouped samples (OR = 1.48, 95% CI = 1.14-1.92, P = 0.003) after adjusting for age and body mass index (BMI). In contrast, there was no association of rs1884613 with T2D in the whole samples and male in our case-control study and meta-analysis.


CONCLUSIONS
Our results suggest that rs1884613 contributes to susceptibility to prediabetes, whereas this polymorphism may not play an important role in the development of T2D.
Shenzhen Nanshan Center for Chronic Disease Control, Shenzhen 518054, China.
Changyi
C
Wang
Shenzhen Nanshan Center for Chronic Disease Control, Shenzhen 518054, China.
Sihan
S
Chen
Shenzhen Nanshan Center for Chronic Disease Control, Shenzhen 518054, China.
Tao
T
Zhang
Shenzhen Nanshan Center for Chronic Disease Control, Shenzhen 518054, China.
Zhongwei
Z
Chen
Shenzhen Nanshan Center for Chronic Disease Control, Shenzhen 518054, China.
Shengyuan
S
Liu
Shenzhen Nanshan Center for Chronic Disease Control, Shenzhen 518054, China.
Xiaolin
X
Peng
Shenzhen Nanshan Center for Chronic Disease Control, Shenzhen 518054, China.
Jianping
J
Ma
Shenzhen Shekou People's Hospital, Shenzhen 518067, China.
Xiaohong
X
Zhong
Shenzhen Shekou People's Hospital, Shenzhen 518067, China.
Yanqiong
Y
Yan
The Affiliated Hospital, School of Medicine, Ningbo University, Ningbo, Zhejiang 315000, China.
Linlin
L
Tang
The Affiliated Hospital, School of Medicine, Ningbo University, Ningbo, Zhejiang 315000, China.
Yifeng
Y
Mai
School of Medicine, Zhejiang Provincial Key Laboratory of Pathophysiology, Diabetes Center, Ningbo University, Ningbo 315211, China.
Liyuan
L
Han
School of Medicine, Zhejiang Provincial Key Laboratory of Pathophysiology, Diabetes Center, Ningbo University, Ningbo 315211, China.
Shiwei
0000-0001-7682-2877
S
Duan
D000368:Aged; D016022:Case-Control Studies; D003924:Diabetes Mellitus, Type 2 / Q000235:genetics; D005260:Female; D051557:Hepatocyte Nuclear Factor 4 / Q000235:genetics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D011236:Prediabetic State / Q000235:genetics*; D011401:Promoter Regions, Genetic
C496592:HNF4A protein, human; D051557:Hepatocyte Nuclear Factor 4